Gastrointestinal Cancer Research - Penn State Cancer Institute
Gastrointestinal Cancer Research
Research into gastrointestinal cancer at Penn State Cancer Institute is conducted by our dedicated gastrointestinal cancer team. See current clinical trials and members of that team here.
Clinical Trials
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
Antibiotics use and chemotherapy in colon cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
Psychosocial Challenges and Educational/Occupational Aspirations of Adolescent/Young Adult Cancer Survivors
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Cancer biobank for developing novel diagnostic biomarkers and therapeutic targets
Understanding Patient Preference on Colorectal Cancer Screening Options
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) A022101
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
A Pilot Study to Evaluate the Feasibility, Safety, and Efficacy of Cannabigerol/Cannabidiol Oil for Chemotherapy-Induced Peripheral Neuropathy
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer.
Gastrointestinal Neuroendocrine Tumor Clinical Database
CTG-CO32: The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation VS. Chemoradiotherapy for Early Rectal Cancer
Disease Team Members
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
 |
Amanda | Cooper | MD | ||
 |
Walter | Koltun | MD | ||
 |
Abraham | Mathew | MD | ||
 |
Matthew | Moyer | MS, MD | ||
 |
Nabeel | Sarwani | MD | ||
 |
Ian | Schreibman | MD | ||
 |
Jeffrey | Scow | MD | ||
 |
Leonard | Tuanquin | MD | ||
 |
Nelson Shu-Sang | Yee | MD, PhD, RPh |
Research into gastrointestinal cancer at Penn State Cancer Institute is conducted by our dedicated gastrointestinal cancer team. See current clinical trials and members of that team here.
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis
Antibiotics use and chemotherapy in colon cancer
The COVID-19 and Cancer Consortium (CCC19) Registry
Psychosocial Challenges and Educational/Occupational Aspirations of Adolescent/Young Adult Cancer Survivors
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) (NRG-GI008)
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
Cancer biobank for developing novel diagnostic biomarkers and therapeutic targets
Understanding Patient Preference on Colorectal Cancer Screening Options
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur) A022101
A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
A Pilot Study to Evaluate the Feasibility, Safety, and Efficacy of Cannabigerol/Cannabidiol Oil for Chemotherapy-Induced Peripheral Neuropathy
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction (GEJ) Cancer.
Gastrointestinal Neuroendocrine Tumor Clinical Database
CTG-CO32: The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation VS. Chemoradiotherapy for Early Rectal Cancer
| First Name | Last Name | Title | Role | ||
|---|---|---|---|---|---|
|
Amanda | Cooper | MD | ||
|
Walter | Koltun | MD | ||
|
Abraham | Mathew | MD | ||
|
Matthew | Moyer | MS, MD | ||
|
Nabeel | Sarwani | MD | ||
|
Ian | Schreibman | MD | ||
|
Jeffrey | Scow | MD | ||
|
Leonard | Tuanquin | MD | ||
|
Nelson Shu-Sang | Yee | MD, PhD, RPh |